MHRA sets out regulatory roadmap for microbiome-based medicines

Key Summary MHRA has published a position paper that sets out regulatory roadmap for microbiome-based medicines. MBMPs work by modulating, restoring, or replacing the human microbiome. Some international regulators have approved donor-derived microbiota products to treat Clostridioides difficile ( C. difficile ) infections. The Medicines and Healthcare products Regulatory Agency ( MHRA ) has…